AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05695066 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Preoperative fasting instruction
Description: Patients parents instructed to stop enteral feeding at a specified time before predicted anesthesia induction
Study NCT05695066 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative fasting instruction
Description: Patients parents instructed to stop enteral feeding at a specified time before predicted anesthesia induction
Study NCT04767438 — intervention group
Intervention type: OTHER
Intervention: Pregnant women
Description: All pregnant women that present to the 12-week scan in the Obstetrics Unit
Study NCT05153525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intermittent boluses of Cisatracurium
Description: Thirty children with ARDS will be treated with intermittent boluses of Cisatracurium (0.1-0.15 mg/kg/dose).
Study NCT05153525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of Cisatracurium for 24 hours
Description: Thirty children with ARDS will be treated with intravenous infusion of Cisatracurium titrated from 1 mic/kg/min till reaching the desired effect for 24 hours.
Study NCT04849715 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: parsaclisib
Description: parsaclisib will be administered orally once daily.
Study NCT04849715 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rituximab
Description: rituximab is administered IV on Day 1 of each 28-day cycle for 6 cycles.
Study NCT04849715 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: rituximab
Description: rituximab is administered IV on Day 1 of each 28-day cycle for 6 cycles.
Study NCT04849715 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bendamustine
Description: bendamustine is administered IV on Day 1 and 2 of each 28-day cycle for 6 cycles.
Study NCT04849715 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: bendamustine
Description: bendamustine is administered IV on Day 1 and 2 of each 28-day cycle for 6 cycles.
Study NCT04849715 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo will be administered orally once daily
Study NCT04929080 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JS004 , Recombinant humanized IgG4k monoclonal antibody specific to BTLA for injection Intravenous infusion
Description: 200mg:JS004 , Recombinant humanized IgG4k monoclonal antibody specific to BTLA for injection Intravenous infusion
Study NCT04929080 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JS004 , Recombinant humanized IgG4k monoclonal antibody specific to BTLA for injection Intravenous infusion
Description: 600mg:JS004 , Recombinant humanized IgG4k monoclonal antibody specific to BTLA for injection Intravenous infusion
Study NCT04929080 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JS001 and JS004
Description: Part B: 100mg JS004 + 240mg JS001 or 200mg JS004+ 240mg JS001
Study NCT05801614 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Low carb diet
Description: Low calori diet
Study NCT06328309 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation treatment
Description: This group is given rehabilitation treatment. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
Study NCT06328309 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rehabilitation treatment
Description: This group is given rehabilitation treatment. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
Study NCT06328309 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Myofascial Release Therapy
Description: Myofascial release, also known as fascial release or fascial manipulation, is a physical therapy used to treat muscle and fascial tissue tension or pain. It involves applying appropriate pressure and stretching to release tight fascia and soft tissues, improving blood circulation, alleviating pain, and promoting rehabilitation. Myofascial release therapy is commonly used to treat muscle spasms, chronic pain, skeletal and joint issues, among others.
Study NCT05768360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Savolitinib
Description: The subjects will receive single dose of oral film-coated tablet of Savolitinib A dose on Day 1 of Period 2 within 25 minutes \[+ 5 minutes\] from the start of meal.
Study NCT05768360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: The subjects will receive single dose of oral uncoated tablet of Digoxin Dose B on Day 1 of Period 1 and Period 2 within 25 minutes \[+ 5 minutes\] from the start of meal.
Study NCT05768360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride
Description: The subjects will receive single dose of oral film-coated tablet of Metformin Hydrochloride Dose D on Day 1 of Period 1 and Period 2 within 25 minutes \[+ 5 minutes\] from the start of meal.
Study NCT05768360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: The subjects will receive single dose of oral film-coated tablet of Rosuvastatin Dose E on Day 1 of Period 1 and Period 2 within 25 minutes \[+ 5 minutes\] from the start of meal.
Study NCT05768360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: The subjects will receive single dose of oral solution of Furosemide Dose C on Day 1 of Period 1 and Period 2 within 25 minutes \[+ 5 minutes\] from the start of meal.
Study NCT05895591 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anti-aging cosmetic care product
Description: * frequency of application: Once a day (in the morning)~* modalities of application: Apply the cream on face (according to normal conditions of use) and on treated forearm, massage until complete penetration~* area: The whole face, neck, neckline and one randomized forearm (external photo-exposed area) the other forearm is untreated~* duration of investigational product application: 56 days (a window of + 72 hours is allowed)~* quantity: 2 pressures of product for the whole face, neck and neckline and 1 pressure of product for the treated forearm
Study NCT04536207 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cryotherapy (apparatus)
Description: Cryotherapy is a pain treatment that uses a method of localized freezing temperatures to deaden an irritated nerve. Cryotherapy is also used as a method of treating localized areas of some cancers (called cryosurgery), such as prostate cancer and to treat abnormal skin cells by dermatologists
Study NCT04990713 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Serratus Plane Block (Local Anesthetic) and Intercostal Block (Local Anesthetic)
Description: Patients will receive local anesthetic via serratus plane block as opposed to saline placebo
Study NCT04990713 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Serratus Plane Block (Placebo) and Intercostal Block (Local Anesthestic)
Description: Patients will receive saline placebo via serratus plane block
Study NCT05756036 — intervention group
Intervention type: OTHER
Intervention: None Observational study
Description: Non interventional study
Study NCT05669651 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: Fecal microbiota transplantation (FMT) refers to the transplantation of functional flora from healthy people's feces into patients' intestines to rebuild new intestinal flora and achieve the treatment of intestinal and parenteral diseases. In this study, 100 patients with recurrent hepatic encephalopathy were randomly divided into 1:1 groups to receive FMT with different amounts of bacteria, observe the therapeutic effect and adverse reactions of hepatic encephalopathy, and evaluate the effectiveness and safety of the two groups of patients. At the same time, the blood and stool samples of patients with recurrent hepatic encephalopathy before and after FMT were collected clinically, the composition of bile acid and other metabolites in stool and serum samples was analyzed, and the effective core flora was identified to clarify the mechanism of intestinal bacteria transplantation for the treatment of recurrent hepatic encephalopathy.
Study NCT05621174 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dexamfetamine
Description: Magisterial Dexamfetamine
Study NCT05621174 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dexamfetamine
Description: Tentin
Study NCT05557305 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Videogame therapy
Description: There will be 5 video game-type applications for virtual therapy, each with a specific therapeutic objective, which will be administered by trained personnel, depending on the characteristics of each patient.
Study NCT05557305 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy
Description: Occupational therapy with different play materials
Study NCT06457841 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Direct Discrimination
Description: Simulated racial discrimination that is received directly from a perpetrator, commonly experienced in everyday lives by African American individuals
Study NCT06457841 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vicarious Discrimination
Description: Hearing or observing racial discrimination experienced by another person of the same racial background
Study NCT05047848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: chidamide 30mg orally，Biw
Study NCT05047848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant 500mg i.m. injections every 28 days (Cycle n Day 1) with 1 additional dose on Day 15 of Cycle 1
Study NCT05330091 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Once Daily Women's Probiotic
Description: Active product
Study NCT05330091 — intervention group
Intervention type: OTHER
Intervention: Placebo
Description: Placebo product
Study NCT05490927 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Microaggression Recall and Relapse Analogue Task
Description: Participants will engage in a microaggression recall task followed by the McKee Experimental Relapse Analogue Task
Study NCT06197620 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thread embedding acupuncture and standard therapy
Description: In the treatment, thread embedding acupuncture was performed using a needle containing polydioxanone (PDO) thread at the EX-B2 acupuncture point (12.5 mm lateral to the spinous process) at the level of the 1st lumbar vertebra with an insertion angle perpendicular to the skin surface. All patients are also given standard therapy after surgery in the form of intravenous Paracetamol 1000 mg, 3 times a day.
Study NCT04832880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib Oral Tablet [Olumiant]
Description: Baricitinib 4 mg die (2 mg for patients aged > 75 years) for 10 days.
Study NCT04832880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: Intravenous remdesivir 200 mg on day 1, followed by remdesivir 100 mg die until day 10
Study NCT04832880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Intravenous dexamethasone 6 mg for 10 days
Study NCT05880173 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: FIB4
Description: Diagnostic procedure :~FIB4 blood tests in medical analysis laboratories. If FIB4 positive, Non invasive spacialized evaluation (transient elastography and FibroMeter) by a specialist and if necessery liver biopsy, endoscopy and/or echography
Study NCT05260762 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Arabinoxylan
Description: Dietary fiber product
Study NCT05260762 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Potato starch
Study NCT04703491 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive and full-featured intervention
Description: Participants will go through an automated program. Participants will learn and practice the techniques of CBT through multimedia elements. They will play games based on Cognitive Bias Modification (CBM) paradigms, practice mindfulness, and chat with an automated empathic chatbot.
Study NCT06457841 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Daily Hassles
Description: Day-to-day stressors associated with school, work, finances
Study NCT06301711 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation therapy
Description: The study lasted 10 days for each patient. During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.~Particularly, due to dysphagia, the patients enrolled might face difficulty in eating. For patients who were able to finish intake via mouth by compensatory means, the consistency, type, and size of food bolus was arranged. For those who cannot acquire sufficient nutrition through oral intake, the nasogastric tube feeding was provided.
Study NCT06301711 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rehabilitation therapy
Description: The study lasted 10 days for each patient. During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.~Particularly, due to dysphagia, the patients enrolled might face difficulty in eating. For patients who were able to finish intake via mouth by compensatory means, the consistency, type, and size of food bolus was arranged. For those who cannot acquire sufficient nutrition through oral intake, the nasogastric tube feeding was provided.
Study NCT06301711 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stellate ganglion block
Description: Based on the invention above, the patients in the observation group were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
Study NCT06301711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Hydrochloride
Description: Based on the invention above, the patients in the observation group were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
Study NCT04703491 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Feature-limited CCBT
Description: Participants will be going through an automated program. Participants will learn and practice the techniques of CBT in a plain-text format with reduced features
Study NCT04703491 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Waitlist control
Description: Participants will be put on a waitlist for a period of 6 weeks.
Study NCT06352450 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Active isolated stretching (AIS)
Description: Active isolated stretching (AIS) is a technique that involves stretching specific muscles or muscle groups while actively engaging the opposing muscles. It typically involves holding a stretch for 1-2 seconds and then releasing. This method aims to improve flexibility, increase range of motion, and enhance muscle function.
Study NCT06352450 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Myofascial release (MFR)
Description: Myofascial release (MFR) is a technique used to release tension and tightness in the fascia, which is the connective tissue that surrounds and supports muscles and organs. It involves applying gentle, sustained pressure to specific areas of the body to help relax the fascia and alleviate restrictions. MFR aims to improve mobility, reduce pain, and enhance overall movement and function.
Study NCT06153472 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VR-based intervention
Description: The Virtual Reality-based sensory stimulation intervention will last for up to fourteen days, with all interventions administered by a research team. The primary outcomes will include delirium incidence, duration, and severity. The secondary outcomes will encompass patients' psychological well-being (post-traumatic stress disorder, sleep quality, and ICU memory), patients' clinical outcomes, and other outcomes (quality of life, independence, and cognitive function).
Study NCT04790071 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physical therapy
Description: Conventional physical therapy: The patients received physical therapy to the shoulder, transcutaneous electrical nerve stimulation, and stretching and strengthening exercises (5 days per week for three weeks in a total of 15 sessions).
Study NCT04790071 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physical therapy plus dry needling
Description: Conventional physical therapy plus dry needling: The patients received physical therapy to the shoulder, including transcutaneous electrical nerve stimulation, stretching, and strengthening exercise (5 days per week for three weeks in a total of 15 sessions). And also, a total of 3 dry needling sessions were applied at 7-day intervals.
Study NCT01471925 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nexium®
Study NCT01471925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazol (40mg) + Sdium Bicarbonate (721mg)
Study NCT05826847 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prone Positioning
Description: Prone positioning will be performed according to ICU local protocol with trained provider teams.
Study NCT05826847 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracoabdominal Binding
Description: Thoracoabdominal binding will be used in semi-recumbent position (supine at 45º) and titrated to obtain a 20-30% decrease in chest wall compliance and 1-3 cm H2O increase in end-expiratory gastric pressure during steady-state breathing
Study NCT05826847 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Control
Description: ARDS patients at spontaneous breathing onset on pressure support ventilation mode in supine position at 45º degrees, performed under standard PEEP according to ARDSNet strategy and individualized PEEP applied in random order.
Study NCT05340790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose 1 to 5 of Antimicrobial Peptide PL-18 Vaginal Suppositories
Description: Escalating doses of 1 mg (0.1%)、2.5mg (0.25%)、5 mg (0.5%)、10mg (1%)、15 mg (1.5%)；single dose administration；topical vaginal suppository ；multiple-dose administration after single dose administration a 3-day wash out period ; once-daily for 6 consecutive days;
Study NCT05340790 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo dose 1 to 5 of Antimicrobial Peptide PL-18 Vaginal Suppositories
Description: Dose 1、2、3、4 and 5 of Antimicrobial Peptide PL-18 Vaginal Suppositories respective placebos；single dose administration；topical vaginal suppository ；multiple-dose administration after single dose administration a 3-day wash out period ; once-daily for 6 consecutive days;
Study NCT04944524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Description: 1. Tofacitinib 5mg twice a day for 12months;~2. Basic treatment with prednisone. (1) the initial dose of prednisone (or equivalent): 0.8mg/kg/day. (2) Glucocorticoids tapering: after two weeks' usage of initial glucocorticoids dose, glucocorticoids can be tapered if there's no disease activity (BVAS/WG=0) or at least 50% reduction of BVAS/WG and no new manifestations. Prednisone (or equivalent) was reduced to 10mg/d at the time of randomization.